Johannessen Erik, Krushinitskaya Olga, Sokolov Andrey, Philipp Häfliger, Hoogerwerf Arno, Hinderling Christian, Kautio Kari, Lenkkeri Jaakko, Strömmer Esko, Kondratyev Vasily, Tønnessen Tor Inge, Mollnes Tom Eirik, Jakobsen Henrik, Zimmer Even, Akselsen Bengt
Vestfold University College, Tønsberg, Norway.
J Diabetes Sci Technol. 2010 Jul 1;4(4):882-92. doi: 10.1177/193229681000400417.
The growing pandemic of diabetes mellitus places a stringent social and economic burden on the society. A tight glycemic control circumvents the detrimental effects, but the prerogative is the development of new more effective tools capable of longterm tracking of blood glucose (BG) in vivo. Such discontinuous sensor technologies will benefit from an unprecedented marked potential as well as reducing the current life expectancy gap of eight years as part of a therapeutic regime.
A sensor technology based on osmotic pressure incorporates a reversible competitive affinity assay performing glucose-specific recognition. An absolute change in particles generates a pressure that is proportional to the glucose concentration. An integrated pressure transducer and components developed from the silicon micro- and nanofabrication industry translate this pressure into BG data.
An in vitro model based on a 3.6 x 8.7 mm large pill-shaped implant is equipped with a nanoporous membrane holding 4-6 nm large pores. The affinity assay offers a dynamic range of 36-720 mg/dl with a resolution of +/-16 mg/dl. An integrated 1 x 1 mm(2) large control chip samples the sensor signals for data processing and transmission back to the reader at a total power consumption of 76 microW.
Current studies have demonstrated the design, layout, and performance of a prototype osmotic sensor in vitro using an affinity assay solution for up to four weeks. The small physical size conforms to an injectable device, forming the basis of a conceptual monitor that offers a tight glycemic control of BG.
糖尿病大流行的加剧给社会带来了沉重的社会和经济负担。严格的血糖控制可避免有害影响，但当务之急是开发能够在体内长期跟踪血糖（BG）的更新、更有效的工具。这种不连续的传感器技术将受益于前所未有的巨大潜力，并作为治疗方案的一部分缩小目前长达八年的预期寿命差距。
一种基于渗透压的传感器技术采用了一种可逆竞争亲和测定法来进行葡萄糖特异性识别。颗粒的绝对变化会产生与葡萄糖浓度成正比的压力。集成的压力传感器以及由硅微纳制造行业开发的组件将这种压力转化为血糖数据。
一个基于3.6×8.7毫米大的丸状植入物的体外模型配备了一个具有4 - 6纳米大孔的纳米多孔膜。亲和测定法的动态范围为36 - 720毫克/分升，分辨率为±16毫克/分升。一个集成的1×1毫米²大的控制芯片对传感器信号进行采样，用于数据处理并以76微瓦的总功耗将数据传输回读取器。
目前的研究已经证明了一种原型渗透传感器在体外使用亲和测定溶液长达四周的设计、布局和性能。其小尺寸符合可注射装置的要求，构成了一个概念性监测仪的基础，该监测仪可实现对血糖的严格控制。
